MEMBRANE ANCHORING AND FUNCTION OF CD16
MEMBRANE ANCHORING AND FUNCTION OF CD16
批准号:
3455711
负责人:
Periasamy Selvaraj
金额:
$9.88万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1992
资助国家:
美国
项目状态:
已结题
起止时间:
1992-07-01 至 1997-04-30
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The knowledge of the structure and function of Fc receptors is
fundamental in understanding the defense of the immune system. In
humans, the structure and binding properties of three types of IgG Fc
receptors (Fc-gamma-Rs) have been described. Of these Fc-gamma-yRIII
(CD16) has demonstrated to be physiologically important. CD16, is a
glycoprotein of 50-70 kD and is expressed on neutrophils, natural killer
(NK) cells, eosinophils and tissue macrophages. In vivo studies using
CD16 monoclonal antibodies have demonstrated that CD16 plays a major role
In clearing immune complexes from the circulation. CD16 has two distinct
membrane anchors; phosphatidylinositol glycan (PIG) in neutrophils and a
polypeptide in NK cells. CD16 is deficiently expressed in PNH, an
acquired hematopoietic stem cell disease which affect the expression of
PIG-anchored proteins. The proposed research uses CD16 negative PNH
neutrophils to test whether the defect in CD16 expression leads to
abnormal neutrophil functions by comparing the Fc dependent functions of
normal and PNH neutrophils before and after reconstituting CD16
expression. The functional ability of polypeptide-anchored CD16
expression on NK cells will also be compared under the same conditions.
These studies will delineate the consequences of CD16 deficiency on
neutrophils and the influence of membrane anchor on the function of CD16.
This proposal is also focused on establishing stable transfectants
expressing/secreting various forms of CD16. Since no cell lines that
express CD16 are available, the stable transfectants will be an excellent
tool for further structure/function studies. The various forms of CD16
will be purified from large scale cultures of these stable transfectants
and biochemically and functionally characterized. The functionally
characterized purified molecule can be used to define the role of these
receptors in cellular functions. In the future, a purified CD16 may
directly be used therapeutically to treat diseases such as chronic immune
thrombocytopenic purpura and prevent Fc mediated HIV and other viral
infections. Alternatively, complete knowledge of its structure and
function may be useful in designing therapeutic agent for treatment of
these diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Glycolipid-anchored cytokines as breast cancer membrane vaccine adjuvants
-
批准号:8459886
-
项目类别:
-
资助金额:$29.33万
-
财政年份:2009
-
负责人:Periasamy Selvaraj
-
依托单位:
Fc receptor targeted therapy for immune hemolytic anemia
-
批准号:7815744
-
项目类别:
-
资助金额:$1.8万
-
财政年份:2009
-
负责人:Periasamy Selvaraj
-
依托单位:
Glycolipid-anchored cytokines as breast cancer membrane vaccine adjuvants
-
批准号:8066755
-
项目类别:
-
资助金额:$31.2万
-
财政年份:2009
-
负责人:Periasamy Selvaraj
-
依托单位:
Glycolipid-anchored cytokines as breast cancer membrane vaccine adjuvants
-
批准号:8257491
-
项目类别:
-
资助金额:$31.2万
-
财政年份:2009
-
负责人:Periasamy Selvaraj
-
依托单位:
Glycolipid-anchored cytokines as breast cancer membrane vaccine adjuvants
-
批准号:7735970
-
项目类别:
-
资助金额:$32.16万
-
财政年份:2009
-
负责人:Periasamy Selvaraj
-
依托单位:
Recombinant Fc receptor therapeutics for systemic lupus erythematosus
-
批准号:7778229
-
项目类别:
-
资助金额:$17.26万
-
财政年份:2009
-
负责人:Periasamy Selvaraj
-
依托单位:
Recombinant Fc receptor therapeutics for systemic lupus erythematosus
-
批准号:7660806
-
项目类别:
-
资助金额:$20.93万
-
财政年份:2009
-
负责人:Periasamy Selvaraj
-
依托单位:
Fc receptor targeted therapy for immune hemolytic anemia
-
批准号:7558253
-
项目类别:
-
资助金额:$19.38万
-
财政年份:2008
-
负责人:Periasamy Selvaraj
-
依托单位:
Fc receptor targeted therapy for immune hemolytic anemia
-
批准号:7356039
-
项目类别:
-
资助金额:$23.2万
-
财政年份:2008
-
负责人:Periasamy Selvaraj
-
依托单位:
Regulation of CD32A in neutrophils
-
批准号:6826289
-
项目类别:
-
资助金额:$30.4万
-
财政年份:2002
-
负责人:Periasamy Selvaraj
-
依托单位:
Regulation of CD32A in neutrophils
-
批准号:6689994
-
项目类别:
-
资助金额:$30.4万
-
财政年份:2002
-
负责人:Periasamy Selvaraj
-
依托单位:
Regulation of CD32A in neutrophils
-
批准号:7149177
-
项目类别:
-
资助金额:$28.82万
-
财政年份:2002
-
负责人:Periasamy Selvaraj
-
依托单位:
Regulation of CD32A in neutrophils
-
批准号:6573536
-
项目类别:
-
资助金额:$29.93万
-
财政年份:2002
-
负责人:Periasamy Selvaraj
-
依托单位:
Regulation of CD32A in neutrophils
-
批准号:6984104
-
项目类别:
-
资助金额:$29.69万
-
财政年份:2002
-
负责人:Periasamy Selvaraj
-
依托单位:
PILOT--MODIFICATION OF MELANOMA CELLS WITH GPI-ANCHORED IL-2
-
批准号:6235803
-
项目类别:
-
资助金额:$5.56万
-
财政年份:1997
-
负责人:Periasamy Selvaraj
-
依托单位:
GPI-ANCHORED MOLECULES AS THERAPEUTIC VACCINES
-
批准号:2114630
-
项目类别:
-
资助金额:$14.76万
-
财政年份:1996
-
负责人:Periasamy Selvaraj
-
依托单位:
GPI-ANCHORED MOLECULES AS THERAPEUTIC VACCINES
-
批准号:2683653
-
项目类别:
-
资助金额:$19.32万
-
财政年份:1996
-
负责人:Periasamy Selvaraj
-
依托单位:
GPI-ANCHORED MOLECULES AS THERAPEUTIC VACCINES
-
批准号:2390932
-
项目类别:
-
资助金额:$18.54万
-
财政年份:1996
-
负责人:Periasamy Selvaraj
-
依托单位:
GPI-ANCHORED MOLECULES AS THERAPEUTIC VACCINES
-
批准号:2895542
-
项目类别:
-
资助金额:$19.45万
-
财政年份:1996
-
负责人:Periasamy Selvaraj
-
依托单位:
MEMBRANE ANCHORING AND FUNCTION OF CD16
-
批准号:2065797
-
项目类别:
-
资助金额:$11.52万
-
财政年份:1992
-
负责人:Periasamy Selvaraj
-
依托单位:
海外基金